H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Electrocore (ECOR) today and set a price target of $3.00. The company’s shares closed last Monday at $1.63.
According to TipRanks.com, Ramakanth is a 5-star analyst with an average return of 31.0% and a 52.1% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Corvus Pharmaceuticals, and Cellectar Biosciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Electrocore with a $3.70 average price target.
See today’s analyst top recommended stocks >>
Electrocore’s market cap is currently $74.09M and has a P/E ratio of -2.10. The company has a Price to Book ratio of 2.72.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
electroCore, Inc. is a commercial-stage bio-electronic medicine company, with a platform non-invasive vagus nerve stimulation therapy focuses on neurology and rheumatology. The company’s therapy, gammaCore, has pharmacologic effects on the peripheral and central nervous systems, which modulate neurotransmitters and immune function. It focuses on acute treatment of migraine and episodic cluster headache. The company was founded by Joseph P. Errico, Steve Mendez, Peter S. Staats and Thomas J. Errico in September 2005 and is headquartered in Morris Plains, NJ.
